Lung Cancer clinical trials in Alaska

10 actively recruiting lung cancer trials at 3 sites across Alaska.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03851445

Sites in Alaska:

Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Anchorage Radiation Therapy Center — Anchorage, Alaska
Alaska Breast Care and Surgery LLC — Anchorage, Alaska
Alaska Oncology and Hematology LLC — Anchorage, Alaska
Alaska Women's Cancer Care — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04402788

Sites in Alaska:

Katmai Oncology Group — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group

NCT ID: NCT05235165

Sites in Alaska:

Providence Alaska Medical Center — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer

NCT ID: NCT07144280

Sites in Alaska:

Alaska Oncology and Hematology — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-…

Sponsor: Bristol-Myers Squibb

NCT ID: NCT07063745

Sites in Alaska:

Alaska Oncology and Hematology — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE

NCT ID: NCT06712316

Sites in Alaska:

Alaska Oncology and Hematology, LLC — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05642572

Sites in Alaska:

Katmai Oncology Group — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03191149

Sites in Alaska:

Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Anchorage Radiation Therapy Center — Anchorage, Alaska
Alaska Breast Care and Surgery LLC — Anchorage, Alaska
Alaska Oncology and Hematology LLC — Anchorage, Alaska
Alaska Women's Cancer Care — Anchorage, Alaska

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

Sponsor: Bristol-Myers Squibb

NCT ID: NCT06855771

Sites in Alaska:

Alaska Oncology and Hematology — Anchorage, Alaska

View on ClinicalTrials.gov →

Recruiting Academic/Other

Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess s…

Sponsor: Addario Lung Cancer Medical Institute

NCT ID: NCT06486428

Sites in Alaska:

Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html — Multiple Locations, Alaska

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20